Tageos Launches World’s Smallest, Best-Performing RFID Inlay for Latest Medication Packaging Types Satisfying ARC Spec S and DoseID Requirements
Montpellier, France, August 25, 2021 – Tageos, a global leader in RFID inlays and tags, today launched its EOS-202 U9 RAIN RFID inlay. With the smallest form factor available today for healthcare and pharmaceutical applications, the new inlay has successfully passed latest tests specified by the Auburn University RFID Lab Spec S. Furthermore, EOS-202 U9 is certified by DoseID as suitable for a broad range of pharmaceutical and healthcare purposes.
The COVID-19 pandemic has highlighted the need for high-performance, resilient healthcare solutions worldwide. RFID technology contributes strongly to that by providing products for seamlessly tracking and tracing pharmaceutical items on a unit-of-use basis. DoseID, an industry Alliance for the use of RFID technology in the healthcare and pharmaceutical space certifies RFID inlays for tracking of pharmaceuticals.
Superior solution for unit-of-use medications
With the EOS-202 U9, Tageos is not simply expanding the range of DoseID certified and ARC Spec S approved inlays designed for unit-of-use medications and specimens in pharmaceutical applications. The French-headquartered RFID supplier is fundamentally upgrading that range with a product of unique capabilities. The new UHF product features a sophisticated, very-small-footprint antenna design measuring just 20×10 mm (wet inlay finished size 22×12 mm) alongside NXP’s state-of-the-art UCODE9 IC. The IC complies with the EPC Class 1 Gen 2 protocol and the ISO 18000-6c standard for global use, and features auto-adjust technology, unique brand identifiers, and pre-serialized 96-bit EPC memory.
Suitable for tagging all latest items specified by ARC Spec S
The chip and the antenna design tailored to it make EOS-202 U9 the market’s smallest RAIN RFID inlay (as of August 2021) to exhibit strong performance across all types of items currently tested according to ARC Spec S for healthcare and pharmaceutical applications.
Its industry-leading read sensitivity and reliability, even in dense RFID tag populations, make the EOS-202 U9 viable for use across the latest portfolio of tested items outlined by ARC Spec S, including clear and amber liquid glass vials, clear glass powder vials, plastic/COC syringes, plastic syringe caps and plastic blow-fill- seal vials. That performance edge pays off in a wide range of hospital, pharmaceutical and inventory management workflows, and comes without any size disadvantage compared to other existing certified inlays.
The new EOS-202 U9 high-performance UHF product underlines Tageos’ commitment to deliver innovative, high-quality RFID inlays, confirmed by the company’s award of the ARC Quality Certification for the design and manufacture of its RFID inlays and tags. The new inlay is available in dry, wet, and paper-face formats in large quantities as of now.
Providing the healthcare sector with the ultimate ‘one-size-fits-all’ solution
“The new EOS-202 U9 inlay underpins our strong commitment to always provide our customers with the most advanced products in terms of maximum performance, quality and sustainability. With its unique combination of the smallest size and optimum read characteristics in challenging environments, the new inlay provides the healthcare and pharmaceutical sector with the ultimate ‘one-size-fits-all’ solution”, said Chris Reese, Head of Product Management at Tageos. “Because of its broad range of applications, we consider the EOS-202 U9 as a true breakthrough product in the market”.
Tageos customer and DoseID founding member Kit Check, the leading provider of automated medication tracking and diversion detection solutions for hospital pharmacies in the U.S., expressed its satisfaction with the new product. “We are excited to have access to a new product that combines the smallest size in the market with unique suitability for all relevant packaging items. It certainly looks like the EOS-202 U9 delivers on its ‘one-size-fits-all’ promise – and that is good news for us and for all of our customers”, said Kevin MacDonald, co-founder and CEO of Kit Check.
DoseID also welcomes the launch of the new Tageos EOS-202 U9 inlay: “It’s good to see our list of certified inlays growing. The fact that there is now a product that passes all ARC Spec S tests also confirms, our certification and testing concept makes it very easy for customers to choose the right solution”, said Tim Kress-Spatz member of the Board of Directors at DoseID.